Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level.
Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level.
复制标题
DOI：
10.6065/apem.2018.23.1.14
复制
发表时间：
2018-03
影响因子：
2.2
通讯作者：
Han HS
中科院分区：
文献类型：
--
作者：
Park J;Hwang TH;Kim YD;Han HS
在促性腺激素释放激素类似物（GnRHa）治疗期间和治疗后，中枢性早熟（CPP）中报告的体重指数（BMI）变化不一致。因此，我们研究了接受GnRHa治疗的特发性CPP（ICPP）女孩的生长参数，直至达到接近最终身高（NFH）。 根据59例接受GnRHa治疗后获得NFH的ICPP女孩的病历，比较超重（BMI≥ 85百分位数）和正常体重（BMI<85百分位数）组的生长学变化。将BMI变更为受试者实足年龄（BMISDS-CA）和骨龄（BMISDS-BA）的标准差评分（BMISDS）。 治疗开始时超重（包括肥胖）的发生率较高（35.6%）。治疗开始时的预测成人身高（PAH）明显短于父母身高（MPH），而治疗结束时的PAH接近MPH，NFH大于MPH。GnRHa治疗期间超重组身高增长速度（HV）高于正常体重组，但治疗后两组无差异，直至NFH。BMISDS-CA和BMISDS-BA在治疗期间均显著增加，但在治疗后均显著降低，直至NFH。在NFH时，BMISDS与基线时无差异。在正常体重组中，两种BMISDS在治疗期间均增加，并维持至NFH。在超重组中，BMISDS在治疗期间均未发生变化，但在治疗后下降，直至NFH。 两组患者在GnRHa治疗期间和治疗后至NFH期间的BMISDS变化的不同模式与GnRHa治疗期间的不同HV有关。
Reported changes in body mass index (BMI) in central precocious puberty (CPP) during and after gonadotropin-releasing hormone analog (GnRHa) treatment are inconsistent. We, therefore, investigated auxological parameters in GnRHa-treated girls with idiopathic CPP (ICPP) until attainment of near final height (NFH). From the medical records of 59 ICPP girls who attained NFH after GnRHa therapy, auxological changes were compared between overweight (BMI≥85th percentile) and normal-weight (BMI<85th percentile) groups. BMIs were changed into standard deviation scores (BMISDSs) for subject chronologic age (BMISDS-CA) and bone age (BMISDS-BA). The incidence of overweight including obesity was high at the start of therapy (35.6%). The predicted adult height (PAH) at start of therapy was significantly shorter than the midparental height (MPH), whereas PAH at end of therapy approached MPH, and NFH was greater than MPH. Height velocity (HV) in the overweight group was higher during GnRHa therapy than that in the normal-weight group, but those in the two groups were not different after therapy until NFH. Both BMISDS-CA and BMISDS-BA increased significantly during therapy, but both BMISDSs decreased significantly after therapy until NFH. At NFH, neither BMISDS was different from that at baseline. In the normal-weight group, both BMISDSs increased during therapy and were maintained until NFH. In the overweight group, neither BMISDS changed during therapy, but there was a decrease after therapy until NFH. The different patterns of BMISDS change during and after GnRHa therapy until NFH between the 2 groups were related to the different HV during GnRHa therapy.